Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

Rhea-AI Summary

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) reported its financial results for Q1 2022, highlighting a net loss of $6.1 million ($0.24 per share), an improvement from a loss of $8.9 million ($0.38 per share) in Q1 2021. Cash and equivalents decreased to $28.9 million from $34.9 million at year-end 2021. R&D expenses fell to $4.8 million from $7.4 million, while G&A expenses also decreased to $1.3 million from $1.8 million. The company is expanding its clinical strategy into new anti-fibrotic indications while discontinuing the Open Label Part of the Armor Study, having achieved its objectives.

Positive

• Reduced net loss from $8.9 million in Q1 2021 to $6.1 million in Q1 2022.
• Decreased R&D expenses from $7.4 million in Q1 2021 to $4.8 million in Q1 2022.
• Discontinuation of the Open Label Part of the Armor Study indicates successful objective completion.

Negative

• Total cash and equivalents declined from $34.9 million at December 31, 2021, to $28.9 million as of March 31, 2022.
• Financial expenses increased from a net income of $0.2 million in Q1 2021 to a loss of $0.05 million in Q1 2022.

TEL AVIV, Israel, May 17, 2022 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases reports financial results for the three months ended March 31, 2022.

 

 

Recent Developments

• Announced that Company's clinical development strategy will expand into new anti-fibrotic indications to maximize the potential of its lead compound, Aramchol while at the same time discontinuing the Open Label Part of the Armor Study having reached its objectives.
• Company evaluating its strategic alternatives and its structuring to best enhance shareholder value and achieve its goals.

Financial Summary – First Quarter 2022 vs. First Quarter 2021:

• Cash and cash equivalents, restricted cash and marketable debt securities totaled $28.9 million as of March 31, 2022, compared to $34.9 million at December 31, 2021.
• Net loss amounted to $6.1 million, or $0.24 per share, for the three months ended March 31, 2022, compared to a net loss of $8.9 million, or $0.38 per share, for the three months ended March 31, 2021.
• Research and development expenses amounted to approximately $4.8 million for the three months ended March 31, 2022, compared to approximately $7.4 million for the three months ended March 31, 2021. The decrease resulted primarily from a decrease in drug development expenses.
• General and administrative expenses amounted to approximately $1.3 million for the three months ended March 31, 2022, compared to approximately $1.8 million for the three months ended March 31, 2021. The decrease in general and administrative expenses for the three months ended March 31, 2021 resulted primarily from a decrease in salaries and benefits.
• Financial expense, net amounted to $0.05 million for the three months ended March 31, 2022, compared to financial income, net of $0.2 million for the three months ended March 31, 2021.

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide and recently initiated a first in human study.

Forward-Looking Statements:

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to Galmed's objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that Galmed intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause Galmed's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the timing and cost of Galmed's pivotal Phase 3 ARMOR trial, or the ARMOR Study or any other pre-clinical or clinical trials; completion and receiving favorable results of the ARMOR Study for Aramchol or any other pre-clinical or clinical trial; the impact of the COVID-19 pandemic; regulatory action with respect to Aramchol or any other product candidate by the FDA or the EMA; the commercial launch and future sales of Aramchol or any other future products or product candidates; Galmed's ability to comply with all applicable post-market regulatory requirements for Aramchol or any other product candidate in the countries in which it seeks to market the product; Galmed's ability to achieve favorable pricing for Aramchol or any other product candidate; Galmed's expectations regarding the commercial market for NASH patients or any other indication; third-party payor reimbursement for Aramchol or any other product candidate; Galmed's estimates regarding anticipated capital requirements and Galmed's needs for additional financing; market adoption of Aramchol or any other product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate; the development and approval of the use of Aramchol or any other product candidate for additional indications or in combination therapy; Galmed's expectations regarding licensing, acquisitions and strategic operations; and the outcome of any evaluation of Galmed's strategic alternatives. More detailed information about the risks and uncertainties affecting Galmed is contained under the heading "Risk Factors" included in Galmed's most recent Annual Report on Form 20-F filed with the SEC on May 2, 2022, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

GALMED PHARMACEUTICALS LTD.
Consolidated Balance Sheets
U.S. Dollars in thousands, except share data and per share data
		As of			As of
		March 31,			December 31,
		2022			2021
		Unaudited			Audited
Assets
Current assets
Cash and cash equivalents	$	3,741		$	2,884
Restricted Cash		114			114
Marketable debt securities		25,001			31,931
Other receivable		843			1,125
Total current assets		29,699			36,054
Right of use assets		361			406
Property and equipment, net		136			145
Total non-current assets		497			551
Total assets	$	30,196		$	36,605
Liabilities and stockholders' equity
Current liabilities
Trade payables	$	4,835		$	4,871
Other payables		812			1,008
Total current liabilities		5,647			5,879
Non-current liabilities
Lease obligation	$	183		$	229
Total non-current liabilities		183			229
Ordinary shares par value NIS 0.01 per share; Authorized 50,000,000; Issued and outstanding:
25,088,414 shares as of March 31, 2022 and December 31, 2021		70			70
Additional paid-in capital		199,229			198,772
Accumulated other comprehensive loss		(616)			(171)
Accumulated deficit		(174,317)			(168,174)
Total stockholders' equity		24,366			30,497
Total liabilities and stockholders' equity	$	30,196		$	36,605
The accompanying notes are an integral part of the interim consolidated financial statements.

 

 

GALMED PHARMACEUTICALS LTD.
Consolidated Statements of Operations (Unaudited)
U.S. Dollars in thousands, except share data and per share data
		Three months ended
		March 31,
		2022			2021
Research and development expenses	$	4,796		$	7,380
General and administrative expenses		1,296			1,752
Total operating expenses		6,092			9,132
Financial expense (income), net		51			(227)
Net loss	$	6,143		$	8,905
Basic and diluted net loss per share	$	0.24		$	0.38
Weighted-average number of shares outstanding used in computing basic and diluted net loss per share		25,088,414			23,374,061

 

GALMED PHARMACEUTICALS LTD.
Consolidated Statements of Cash Flows (Unaudited)
U.S. Dollars in thousands
	Three months ended
	March 31,
	2022			2022
Cash flow from operating activities
Net loss	$	(6,143)		$		(8,905)
Adjustments required to reconcile net loss to net cash used in operating activities
Depreciation and amortization		9				11
Stock-based compensation expense		457				471
Amortization of premium on marketable debt securities		31				21
Interest income from short-term deposits		-				(4)
Loss (Gain) from realization of marketable debt securities		145				15
Finance expenses		(10)				-
Changes in operating assets and liabilities:
Decrease in other accounts receivable		282				28
Decrease in trade payables		(36)				(1,243)
Increase (decrease) in other accounts payable		(187)				320
Net cash used in operating activities		(5,452)				(9,286)
Cash flow from investing activities
Purchase of property and equipment		-				(1)
Investment in available for sale securities		-				(10,007)
Sale (investment) in short term deposits, net		-				2,005
Consideration from sale of available for sale securities		6,309				6,359
Net cash provided by (used in) investing activities		6,309				(1,644)
Cash flow from financing activities
Proceeds from exercise of options (*)		-				(*)
Issuance of Ordinary shares, net of issuance cost		-				17,368
Net cash provided in financing activities		-				17,368
Increase (decrease) in cash and cash equivalents and restricted cash		857				6,438
Cash and cash equivalents and restricted cash at the beginning of the period		2,998				7,060
Cash and cash equivalents and restricted cash at the end of the period	$	3,855		$		13,498
Supplemental disclosure of cash flow information:
Cash received from interest	$	77		$		179
Non-cash transactions:
Recognition of right-of-use asset and lease liability from adoption of ASU 2016-02	$	-		$		497
(*) Represents amount less than $1.

 

 

View original content:https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-reports-first-quarter-2022-financial-results-301548816.html

SOURCE Galmed Pharmaceuticals Ltd.

FAQ

What were Galmed Pharmaceuticals' financial results for Q1 2022?

Galmed reported a net loss of $6.1 million ($0.24 per share) for Q1 2022, an improvement from a $8.9 million loss ($0.38 per share) in Q1 2021.

How much cash did Galmed Pharmaceuticals have at the end of Q1 2022?

As of March 31, 2022, Galmed had $28.9 million in cash and equivalents, down from $34.9 million at the end of 2021.

What changes did Galmed Pharmaceuticals announce regarding their clinical development strategy?

Galmed announced that it will expand into new anti-fibrotic indications while discontinuing the Open Label Part of the Armor Study after achieving its objectives.

What were the R&D expenses for Galmed Pharmaceuticals in Q1 2022?

Research and development expenses for Q1 2022 were approximately $4.8 million, a decrease from $7.4 million in Q1 2021.

What is the current status of Galmed Pharmaceuticals' lead compound, Aramchol?

Aramchol is currently in a Phase 3 registrational study for the treatment of NASH and fibrosis.